Compare Rubrik Inc. Class A Common Stock (RBRK) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rubrik Inc. Class A Common Stock vs Repligen Corporation Common Stock — how do they compare? Rubrik Inc. Class A Common Stock trades at $109.84 (market cap $24.56B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Rubrik Inc. Class A Common Stock is far larger — about 2.2× Repligen Corporation Common Stock's market cap, and Rubrik Inc. Class A Common Stock is more actively traded (2,289,465 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Rubrik Inc. Class A Common Stock for 4 Days and Repligen Corporation Common Stock for 0 Days on average.
| RBRK | RGEN | |
|---|---|---|
Market Cap | $24.56B | $11.14B |
Volume | 2,289,465 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $125.80 | $194.57 |
52-Week Low | $43.81 | $102.87 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $23.96B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rubrik (RBRK) trades at $118.47, down 1.28% on the day, with strong technical momentum showing bullish moving averages and support at $118. The company demonstrates impressive revenue growth, with 2026 revenue reaching $1.5B and recent earnings beats, though profitability remains negative with a -16.5% net margin. Recent news highlights expansion of AI security offerings including Rubrik Code Guardian and strong institutional buying interest.
Rubrik presents a compelling growth story in cybersecurity with 100% analyst buy ratings and $105.08 consensus target, though current price exceeds this. Key risks include persistent losses despite revenue growth and competitive AI security landscape. The stock's technical strength and AI-driven demand create upside potential, but profitability concerns warrant careful monitoring of margin improvement.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rubrik Inc. Class A Common Stock
Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
